unresectable pancreatic cancer
Conditions
Interventions
assignment to kestose-administered and non-administered groups
Sponsors
Hirooka Yoshiki
Ohno Eizaburo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have received sufficient explanation before participating in this study, and have obtained written consent by their own free will with sufficient understanding. 2. Patients aged 20 to 80 at the time of consent. 3. Patients diagnosed with pancreatic cancer based on the diagnostic criteria for pancreatic cancer. 4. Patients with ECOG Performance Status (PS) 0-1.
Exclusion criteria
Exclusion criteria: 1. Patients who have previously undergone gastrointestinal surgery. 2. Patients who have been receiving radiation therapy or chemotherapy. 3. Other patients who are judged to be inappropriate by the investigator and the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of tumor markers and nutritional status in blood tests due to increased effectiveness of insurance treatment for pancreatic cancer with improvement of nutritional status 4, 8 and 12 weeks after administration of kestose with biological marker score. | — |
Secondary
| Measure | Time frame |
|---|---|
| As the nutritional status improved 4, 8 and 12 weeks after the administration of kestose with an anatomical marker score, the effect of insurance treatment for pancreatic cancer increased and the tumor shrinkage rate improved by CT images. | — |
Contacts
Public ContactKazunori Nakaoka
Fujita Health University Hospital
Outcome results
None listed